CSTL Q3 2024 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q3 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$86M+39.5% YoY

Gross Profit

$70M81.8% margin

Operating Income

$5M5.9% margin

Net Income

$2M2.6% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$17M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$515M

Total Liabilities

$74M

Stockholders' Equity

$441M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$61M	+39.5%
Gross Profit	$70M	$50M	+39.9%
Operating Income	$5M	-$10M	+152.7%
Net Income	$2M	-$7M	+132.9%

Revenue Segments

Dermatologic

$65M100%